Investment company RTW Investments has launched a new biotech company called Prolium Bioscience, to advance the development of ICP-B02, a CD20×CD3 bispecific antibody originating from China’s Keymed Biosciences and developed in partnership with InnoCare Pharma. The agreement grants Prolium exclusive rights to develop and commercialise the drug globally in non-oncology indications and outside Asia for oncology. Under the deal, Prolium will pay $17.5m upfront, with potential milestone payments totalling $502.5m, according to a Hong Kong Stock Exchange filing. Keymed and InnoCare will also hold a minority equity stake in Prolium and are eligible for tiered royalties on future net sales. ICP-B02 is a bispecific antibody designed to bind CD20 on tumour cells and CD3 on T cells, redirecting and activating T cells to attack tumour cells through T cell-directed cellular cytotoxicity (TDCC). The therapy is being evaluated in a Phase I/II clinical trial (NCT05210868) in China for relapsed/refractory non-Hodgkin lymphoma (NHL).

Full story : KeyMed partners with US-based biotech Prolium in bispecific antibody deal.